Two Sigma Investments LP boosted its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 21.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 745,029 shares of the biotechnology company’s stock after buying an additional 132,097 shares during the quarter. Two Sigma Investments LP owned 0.45% of Rigel Pharmaceuticals worth $1,714,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Tamarack Advisers LP grew its position in Rigel Pharmaceuticals by 20.9% in the fourth quarter. Tamarack Advisers LP now owns 5,500,000 shares of the biotechnology company’s stock worth $12,650,000 after buying an additional 950,000 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Rigel Pharmaceuticals in the 4th quarter worth approximately $1,341,000. Teachers Advisors LLC boosted its stake in Rigel Pharmaceuticals by 8.0% in the 3rd quarter. Teachers Advisors LLC now owns 320,614 shares of the biotechnology company’s stock worth $1,029,000 after purchasing an additional 23,823 shares during the period. Pura Vida Investments LLC boosted its stake in Rigel Pharmaceuticals by 9.8% in the 4th quarter. Pura Vida Investments LLC now owns 332,056 shares of the biotechnology company’s stock worth $764,000 after purchasing an additional 29,567 shares during the period. Finally, Canada Pension Plan Investment Board boosted its stake in Rigel Pharmaceuticals by 400.0% in the 3rd quarter. Canada Pension Plan Investment Board now owns 250,000 shares of the biotechnology company’s stock worth $803,000 after purchasing an additional 200,000 shares during the period. Hedge funds and other institutional investors own 94.86% of the company’s stock.
A number of research firms have recently weighed in on RIGL. HC Wainwright set a $8.00 price target on shares of Rigel Pharmaceuticals and gave the company a “buy” rating in a report on Friday, January 11th. Cantor Fitzgerald set a $9.00 price target on shares of Rigel Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 3rd. Zacks Investment Research upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Thursday, December 13th. Finally, ValuEngine downgraded shares of Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Rigel Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $7.25.
TRADEMARK VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://sportsperspectives.com/2019/04/02/two-sigma-investments-lp-acquires-132097-shares-of-rigel-pharmaceuticals-inc-rigl.html.
Rigel Pharmaceuticals Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia.
See Also: Is a Roth IRA right for you?
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.